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Reports of resurgence in invasive group A streptococcal (GAS) infections come mainly from affluent
populations with infrequent exposure to GAS. In the Northern Territory (NT) of Australia, high incidence of
invasive GAS disease is secondary to endemic skin infection, serotype M1 clones are rare in invasive infection,
the diversity and level of exposure to GAS strains are high, and no particular strains dominate. Expression of
a plasminogen-binding GAS M-like protein (PAM) has been associated with skin infection in isolates elsewhere
(D. Bessen, C. M. Sotir, T. M. Readdy, and S. K. Hollingshead, J. Infect. Dis. 173:896-900, 1996), and
subversion of the host plasminogen system by GAS is thought to contribute to invasion in animal models. Here,
we describe the relationship between plasminogen-binding capacity of GAS isolates, PAM genotype, and
invasive capacity in 29 GAS isolates belonging to 25 distinct strains from the NT. In the presence of fibrinogen
and streptokinase, invasive isolates bound more plasminogen than isolates from uncomplicated infections (P
< 0.004). Only PAM-positive isolates bound substantial levels of plasminogen by a fibrinogen-streptokinase-
independent pathway (direct binding). Despite considerable amino acid sequence variation within the A1
repeat region of PAM where the plasminogen-binding domain maps, the critical lysine residue was conserved.
Group A streptococci (GAS) cause a variety of superficial
infections, such as impetigo, as well as invasive diseases, in-
cluding bacteremia, necrotizing fasciitis, and myositis. A recent
survey from the tropical “Top End” of the Northern Territory
(NT) found a high incidence of invasive GAS disease, with
rates of bacteremia in non-Aboriginal people (8) comparable
to those that constituted the resurgence in GAS bacteremia
described elsewhere in the Western world (29, 39). Among
Aboriginal people of the Top End, the incidence of GAS
bacteremia is five times that of non-Aboriginal people living in
the same region (8).
In addition to the high incidence of severe GAS infection in
the NT, several other epidemiological features characterize the
GAS isolates from this vast geographic region. Up to 60% of
isolates from the NT do not react with available M-typing sera
(28), while some react with more than one, giving an ambigu-
ous M-typing result (27). This has led to the development of
the vir typing system, which consists of restriction fragment
length polymorphism analysis of the mga regulon (14). vir
typing of strains that cause GAS infection in Aboriginal com-
munities has demonstrated that the diversity and turnover rate
of these strains are much higher than those reported elsewhere
(7). There has been no evidence of a resurgence in severe
invasive infections due to particular strains or any invasive
infection associated with M1 clones (8), which have been re-
sponsible for much of the recent resurgence in GAS bactere-
mia reported elsewhere (31). A recent NT study examining 100
GAS isolates found only two M1 isolates which were not
clonally related or isolated from invasive disease cases (R. J.
Towers, G. Mollinari, K. Bruder-Okando, D. Zell, A. Delvec-
chio, P. Fagan, S. Gardam, M. Hibble, B. Currie, M. J. Walker,
K. S. Sriprakash, and G. S. Chhatwal, Abstr. XVth Lancefield
International Symposium on Streptococci and Streptococcal
Diseases, abstr. P1.02, 2002). Similarly, a study of invasive
GAS disease isolates from 1996 to 2001 in Townsville Hospital,
North Queensland, found that only 5.5% were of the emm1
(gene for M1 protein) sequence type (ST) (R. Norton, H. V.
Smith, N. Wood, E. Siegbrecht, A. Ross, and N. Ketheesan,
Abstr. XVth Lancefield International Symposium on Strepto-
cocci and Streptococcal Diseases, abstr. O2.2, 2002).
The most common focus of invasive infection in the NT is the
skin, with no episodes of pharyngitis underlying GAS bacteremia
in a 6-year retrospective review (8). Rates of GAS skin infection
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are extremely high, due in part to infection of scabies lesions, with
impetigo prevalence rates of up to 70% reported (16).
An important role for plasminogen in invasion of host tissue
barriers has been recognized in several bacterial species (5, 11,
23). Plasminogen is the zymogen of the broad-spectrum serine
protease plasmin, which degrades fibrin clots and extracellular
matrix (ECM) components such as fibronectin, laminin, vitronec-
tin, and proteoglycans. It also activates matrix prometallopro-
teases 1, 3, 9, and 14, which cleave other components of
the ECM, such as collagen (40). Plasminogen is activated to
plasmin by the host activator tissue plasminogen activator and
urokinase plasminogen activator. Colocalization of plasminogen
and tissue plasminogen activator to fibrin(ogen) results in fibri-
nolysis, while urokinase plasminogen activator is the major cell-
bound activator, functioning in cellular invasion (22). Bacterial
plasminogen activators include Pla of Yersinia pestis and strep-
tokinase of group A, C, and G streptococci (5).
Plasminogen binds to the high-affinity GAS plasminogen
receptor plasminogen-binding GAS M-like protein (PAM) (2)
and streptococcal enolase (SEN) (25) by its amino-terminal
lysine-binding kringle domains (21). Cell surface glyceralde-
hyde-3-phosphate dehydrogenase, designated Plr (41), or
streptococcal dehydrogenase (26), has been reported to bind
plasminogen with low affinity.
Plasminogen binds to PAM via lysine residues present in two
tandem repeats, A1 and A2, in the amino-terminal variable
region of PAM (2). The lysine residue found in A1 is respon-
sible for the majority of the plasminogen binding capacity of
PAM (43). This interaction is at least partly mediated by krin-
gle 2 of plasminogen (42).
The PAM phenotype and genotype have been found to be
selectively distributed among GAS strains of emm pattern D
(32), which is reported to be a genetic marker for skin as the
preferred tissue site for infection (3, 4). It has been suggested
that the plasminogen binding capacity of PAM may be impor-
tant for the persistence of GAS in skin infection. Proteolytic
capacity of PAM-bound plasminogen on the surface of GAS
may allow the breakdown of fibrin barriers formed during
wound healing. Alternatively, sequestering of plasminogen by
GAS may diminish the plasminogen available for host immune
response at the infection site (41).
An indirect plasminogen-binding pathway in GAS with a
requirement for streptokinase and fibrinogen has also been
described previously (37, 38). Plasminogen binding by this
pathway has been correlated with the fibrinogen-binding ca-
pacity of various GAS strains (38), and it has been suggested
that fibrinogen bound to M or M-related proteins mediates the
capture of fibrinogen-streptokinase-plasminogen complexes to
the GAS cell surface (10, 37). Evidence for the formation of
the trimolecular complex using purified protein components
has been reported previously (33). The trimolecular complex
bound to the GAS cell surface possesses both plasmin (37) and
plasminogen activator (12) activities.
In a mouse skin infection model, GAS that were preincu-
bated with human plasminogen, human fibrinogen, and exog-
enous streptokinase were more invasive than were untreated
bacteria (24). However, a study of clinical isolates found no
significant association between plasminogen binding and the
invasive potential of the isolates, although the mean plasmin
activity of blood isolates was higher than that of throat isolates
(36). To date, there has been no definitive epidemiological
evidence supporting a relationship between the human plas-
minogen system and GAS in accentuating virulence (5).
Reports suggesting an important role for plasminogen in
both GAS skin disease and invasive disease led us to investi-
gate aspects of plasminogen binding by GAS isolates from the
NT, where a high incidence of both clinical manifestations of
GAS infection prevails. Isolates from uncomplicated infections
and invasive disease cases were examined for plasminogen
binding by the direct and fibrinogen-streptokinase-dependent
(FSD) pathways, fibrinogen binding capacity, PAM genotype,
emm pattern, and emm ST.
(Part of this work was presented as a scientific poster at the
XVth Lancefield International Symposium on Streptococci
and Streptococcal Diseases, October 6-11, 2002, Goa, India
[abstract P2.26].)
MATERIALS AND METHODS
Proteins. Glu-plasminogen was purified from human plasma as previously
described (1). Human fibrinogen (essentially plasminogen free; Sigma, St. Louis,
Mo.) was tested to confirm the absence of contaminating fibronectin by Western
blotting with a rabbit polyclonal antibody against human fibronectin (Sigma).
Plasminogen and fibrinogen were labeled with 125I (Amersham Biosciences,
Arlington Heights, Ill.) by the chloramine T method (19). All labeled proteins
were analyzed for homogeneity by gel electrophoresis and autoradiography in
comparison with nonlabeled proteins.
Bacterial strains, media, and growth conditions. GAS isolates were collected
from patients in the NT between 1990 and 1998. Isolates were collected from
either invasive infections (from normally sterile tissues such as blood) or uncom-
plicated infections (from nonsterile tissues such as skin). The isolates were
largely from Aboriginal Australians because of the high endemicity of GAS
disease in this population (8). GAS isolates were cultured overnight at 37°C in
Todd-Hewitt broth (Difco, Detroit, Mich.) supplemented with 1% yeast extract.
Cells were washed twice with 5 ml of phosphate-buffered saline (0.01 M phos-
phate, 0.14 M sodium chloride [pH 7.4]) containing 0.05% Tween 20 and resus-
pended to an optical density of 1.0 at 600 nm in PBS–0.05% Tween 20 with a 100
mM concentration of the lysine analogue epsilon-amino caproic acid (eACA;
Sigma) added where appropriate.
Molecular typing and emm pattern. vir typing (14) was performed as previ-
ously described. The method used to determine emm STs was modified from the
S. pyogenes emm sequence database (http://www.cdc.gov/ncidod/biotech/strep/
strepindex.htm) and is described briefly here. Chromosomal DNA was prepared
by using the DNeasy tissue extraction kit (Qiagen, Hilden, Germany). PCR
amplification of chromosomal DNA was performed with primers emm1 and
emm2 (http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm) or with primers
VUF and SBR as previously described (15). The resulting PCR product was
purified by using a MinElute gel extraction kit (Qiagen) and sequenced with
BigDye ready reaction mix (Applied Biosystems, Boston, Mass.) using emm1 or
emmseq2 primers. The resulting sequences were compared to emm sequences in
the S. pyogenes emm sequence database.
Determination of the emm pattern was performed as previously described (3,
17), except that annealing temperatures were varied between 56 and 62°C.
Binding assays. The method used to measure the binding of radiolabeled
proteins was performed essentially as previously described (9). Labeled protein
(approximately 70 ng of 125I-plasminogen or 45 ng of 125I-fibrinogen) was added
to 250 l of the cell suspension and incubated for 45 min at room temperature.
When required, fibrinogen (1.5-fold molar excess compared to plasminogen) and
streptokinase (10-fold molar excess compared to plasminogen) (both from
Sigma) were added to the cell suspension. Equimolar concentrations of plasmin-
ogen and streptokinase were added to the cell suspension for selected assays. The
cells were sedimented by centrifugation, and the supernatant was carefully aspi-
rated. Pellet-associated radioactivity was measured with an automatic gamma
counter (Wallac), and the results were expressed as a percentage of input radio-
activity. All measurements were determined in triplicate.
DNA methods. Chromosomal DNA was isolated from streptococcal isolates by
using the Instagene method (Bio-Rad Laboratories, Hercules, Calif.). Genes
encoding M and M-like proteins from GAS strains were PCR amplified from
chromosomal DNA by using primers M1 and M2 (2). The SEN gene was PCR
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amplified from chromosomal DNA by using SENF1 and SENR1 (Table 1). PCR
cycling temperatures were 94, 50, and 72°C for denaturation, annealing, and
extension reactions, respectively. Thirty and 32 cycles were used for amplification
of genes encoding M and SEN, respectively.
For Southern hybridization (30) of PAM genes, PCR products that had been
amplified with the M1 and M2 primers were resolved by agarose gel electro-
phoresis, transferred to a Hybond N nylon membrane (Amersham Bio-
sciences) and cross-linked to the membrane using a UV Stratalinker 1800 (Strat-
agene, La Jolla, Calif.). Prehybridization, hybridization, and detection were
performed by using a digoxigenin-11-ddUTP labeling kit (Boehringer Mann-
heim, Mannheim, Germany) according to the manufacturer’s instructions, except
that blocking was performed with 5% skim milk powder in maleic acid buffer (0.1
M maleic acid, 0.15 M NaCl [pH 7.5]). The PAM oligonucleotide probe (5-C
GACTTAAAA[A/G]CGAGAGACATGA-3) is homologous to the sequence
corresponding to the most conserved residues (RLKN and SERH) in the A1
(DAELQRLKNERHE) and A2 (EAELERLKSERHD) repeats of PAM. The
probe was 3 end labeled with digoxigenin-11-ddUTP according to the manufac-
turer’s instructions.
PCR products that had been amplified with the M1 and M2 primers from
PAM-positive GAS strains were cloned into plasmid pCR2.1 by using the TA
Cloning Kit (Invitrogen, Carlsbad, Calif.). Escherichia coli INVF (Invitrogen)
was transformed with plasmids containing the PAM genes according to the
manufacturer’s instructions. Plasmid DNA was extracted using a QIAprep spin
miniprep kit (Qiagen). Plasmids were screened for the presence of the cloned
PAM gene by Southern hybridization.
DNA sequences were determined by using Terminator Ready reaction mix
(PE Applied Biosystems) and appropriate primers (Table 1).
Statistical analysis. Pearson’s 2 analysis was used to determine associations
between genetic markers and invasive classification. Binding data were analyzed
for differences between PAM status and infection classification using two-way
analysis of variance (ANOVA). Where data (or arcsine-transformed data) did
not fit the assumptions for two-way ANOVA, an unpaired Student t test, Welch
ANOVA (unequal variances), or Wilcoxon and Kruskal-Wallis Rank Sum test
(nonparametric) was used to compare groups separately. A paired Student t test
was used to analyze responses of isolates to different experimental conditions.
Pearson’s (parametric) or Spearman’s (nonparametric) correlation coefficients
(r) were used to describe the relationships between cell surface binding of
radiolabeled proteins.
Nucleotide sequence accession numbers. The DNA sequences of the A1 and
A2 repeat regions of PAM genes were deposited in GenBank. The correspond-
ing accession number for each PAM-positive isolate is given in parentheses:
NS10 (AY351846), NS1133 (AY351847), NS59 (AY351848), NS50.1
(AY351849), NS32 (AY351850), NS13 (AY351851), NS53 (AY351852), NS253
(AY351853), NS223 (AY351854), NS265 (AY351855), NS88.2 (AY351856),
NS455 (AY351857), and NS696 (AY351858).
RESULTS
Genetic analysis of GAS isolates. Characteristics of the 29
clinical isolates from invasive cases (n  14) and uncompli-
cated cases (n 15) of GAS infection are given in Table 2. The
isolates showed considerable genetic diversity, with 25 vir
types, 24 emm STs, and four of the five major emm patterns
represented (Table 2). Together, the 29 isolates represent 25
genetically distinct strains, which are thus not epidemiologi-
cally linked. There were three small clusters of isolates which
were found to be genetically indistinguishable based on the
typing methods used. These were NS730 and NS733 (vir type
2.2, emmST 90 and emm pattern E); NS10, NS13, and NS59
(vir type 24, emmST 53 and emm pattern D); and NS455 and
NS253 (vir type 29.1, emmST 52 and emm pattern D). In this
study, emm pattern was not significantly associated with inva-
sive disease (P  0.148).
GAS isolates were then examined for the presence of genes
encoding the high-affinity plasminogen binding receptors, SEN
and PAM, and for genetic variation within the plasminogen
binding domains of these receptors. All the isolates contained
the SEN gene with both plasminogen binding C-terminal lysine
residues (13, 25) conserved (data not shown). Of the 14 isolates
from invasive disease cases, 5 were PAM positive by Southern
hybridization analysis, while 8 of the 15 isolates from uncom-
plicated infections were PAM positive.
The A1 and A2 repeats of the PAM sequences demonstrate
divergence compared to the repeats in the prototype PAM (2)
(Fig. 1). Isolates of the same vir type had identical A1 and A2
repeats. Except for NS696, all the 13 PAM-positive isolates
possessed the emm pattern D mga regulon.
Plasminogen binding by GAS isolates. To investigate
whether plasminogen binding is associated with the invasive
phenotype in NT isolates, isolates from invasive disease and
uncomplicated infections were compared for this property.
Binding by the direct and FSD pathways was measured (Fig.
2). In the presence of eACA, a competitive inhibitor of lysine-
dependent binding, binding was reduced to 4% of that of input
plasminogen (range, 2 to 11%), except in isolate NS88.2, which
showed a high level of lysine-independent binding of plasmin-
ogen (17%; data not shown).
The presence of the PAM gene had a significant positive
effect on plasminogen binding by both the direct (P  0.036)
and FSD (P  0.026) pathways. Invasive isolates bound more
plasminogen directly than isolates from uncomplicated infec-
tions in the PAM-positive group (P  0.027). In the PAM-
negative group, all of the isolates displayed minimal reactivity
with plasminogen (mean, 7%), and there was no difference in
direct plasminogen binding capacity between invasive and non-
invasive isolates (P  0.180).
In the presence of streptokinase and fibrinogen, isolates from
invasive disease cases bound more plasminogen than isolates
from uncomplicated infections (P  0.004 for effect of invasive
phenotype in two-way ANOVA; P  0.026 for effect of PAM
genotype). There was an absolute requirement for both fibrino-
TABLE 1. Primers designed for DNA analysis
Primer DNA sequence Use
SENF1 5-GGTATGGATGAAAACGACTGGGATG-3 PCR amplification and sequencing of SEN gene
SENR1 5-TGTCGTGACCAACCTAGTCAGCCTG-3
PAMF1 5-ATAAGCAAGAACATCTTGACGG-3 Sequencing of PAM genea
PAMR1 5-CTGTTAATTTCTTGCTTTC-3
PAMF2 5-AAAGGGCTTAAGACTGATTTAC-3
PAMR2 5-GACCAGCTAATTTGCTGTTTGC-3
PAMR3 5-CTTCTCAACATCATCTTTAAGG-3
a The PAM gene sequence was determined by using M13LacZ forward and universal reverse primers (Perkin-Elmer, Boston, Mass.), primers N1 and N2 flanking
the plasminogen-binding site of PAM (5), and the primers listed above, designed to anneal to various sites within the PAM gene.
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gen and streptokinase to significantly increase plasminogen bind-
ing in a representative isolate (Fig. 3). The enhancement of plas-
minogen binding did not occur when streptokinase alone or
fibrinogen alone was added (P  0.05 for both conditions).
Within the small clusters of genetically indistinguishable iso-
lates identified, invasive isolates bound more plasminogen than
isolates from uncomplicated infection by both the direct and
FSD pathways in each case.
Relationships between fibrinogen and plasminogen binding.
The relationship between fibrinogen binding and FSD plas-
minogen binding by the NT GAS isolates was investigated to
determine whether the data were consistent with a model of
capture of fibrinogen-streptokinase-plasminogen complexes by
fibrinogen binding proteins (36). Binding of fibrinogen to GAS
isolates is shown in Fig. 4A. PAM-positive isolates bound more
fibrinogen than PAM-negative isolates (P  0.019). There was
a correlation between fibrinogen binding and FSD plasmino-
gen binding among PAM-positive isolates (r  0.775, P 
0.002) (Fig. 4A). By contrast, PAM-negative isolates did not
show such correlation (r  0.035, P  0.897), nor was there a
correlation between fibrinogen binding and the increase in
plasminogen binding resulting from the addition of streptoki-
nase and fibrinogen (r  0.007, P  0.778)
In PAM-positive isolates, there was a strong correlation be-
tween direct plasminogen binding and FSD plasminogen binding
(r 0.902, P 0.0001) (Fig. 4B) and between direct plasminogen
binding and fibrinogen binding (r  0.806, P  0.001).
DISCUSSION
Subversion of the host plasminogen system renders a patho-
gen capable of degrading ECM proteins and activating a cascade
of metalloproteases, thereby conferring the potential to invade
host tissue barriers. An important role for plasminogen in the
infection process of GAS has been demonstrated in several ani-
mal models (20a, 24, 32a), but as yet no definitive epidemiological
evidence has supported the hypothesis that the human plasmin-
ogen system plays a role in GAS invasive disease.
To our knowledge, this is the first report to demonstrate a
significant relationship between the acquisition of plasminogen
by human clinical isolates from a range of emm STs of GAS
and the propensity to cause invasive diseases. Among PAM-
TABLE 2. Characteristics of the 29 NT GAS isolates
Isolate Clinical origin Invasivecategorya
PAM
statusb
% 125I-
plasminogen
bindingc
% Enhanced
125I-plasminogen
bindingc,d
vir
typee emm ST
f emm
patterng
NS192 Renal transplant, septic (blood) Inv  6  0 29  1 3.2 100 E
NS210 Diabetic ulcer with fever Inv  7  0 29  2 34 22 E
NS414 Wound, cellulitis Inv  4  0 27  2 3.3 11 E
NS452 Cellulitis, wound Inv  7  0 57  1 45 25 E
NS501 Blood Inv  10  1 63  6 61 14 ABC
NS730 Necrotizing fasciitis, pus from left hip Inv  11  0 55  1 2.2 90 E
NS733 Necrotizing fasciitis, wrist aspirate Inv  5  1 29  0 2.2 90 E
NS931 Necrotizing fasciitis, blood Inv  6  0 52  3 57 69 D
NS179 Pustules on foot, bacteremia Inv  9  1 57  1 7.2 9.1 E
NS13 Blood Inv  81  2 89  1 24 53 D
NS88.2 Blood Inv  54  1 60  1 17.4 98.1 D
NS223 Infected central venous catheter (leg),
blood
Inv  27  0 55  2 4 91 D
NS455 Blood Inv  30  1 54  1 29.1 52 D
NS1133 Blood Inv  50  1 81  1 17.1 101 D
NS14 Postoperative wound Uncomp  4  0 27  0 96 102 E
NS236 Sore throat Uncomp  6  0 27  0 111 77 E
NS244 Wound Uncomp  8  0 59  1 14.1 Hybrid emm4/st11014 ABCh
NS297 Skin sore Uncomp  6  1 50  0 3.1 44/61 E
NS474 Wound Uncomp  5  0 24  0 22 58 ABCh
NS488 Sinusitis and persistent pharyngeal pus
well
Uncomp  6  0 5  0 52 12 ABC
NS836 Wound Uncomp  5  0 32  1 46 ck249 D
NS10 Throat Uncomp  44  2 54  0 24 53 D
NS32 Wound Uncomp  34  0 58  1 29.2 101 D
NS50.1 Wound Uncomp  17  1 46  3 12.1 108 D
NS53 Febrile and unwell patient Uncomp  5  0 35  1 29.1 71 D
NS59 Wound Uncomp  44  1 61  1 24 53 D
NS253 Wound Uncomp  15  1 31  6 29.1 52 D
NS265 Wound Uncomp  5  0 21  1 11 56 D
NS696 Throat swab, pharyngitis Uncomp  5  0 7  1 78 1 ABC
a Invasive (Inv) or uncomplicated (Uncomp) GAS infection classification according to sterile or nonsterile tissue site of infection, respectively.
b Positive () or negative () PAM status according to hybridization of M or M-like gene from GAS isolate with an oligonucleotide probe homologous to the A1/A2
repeat of the PAM gene by Southern blot analysis.
c Values are percent binding  standard error of the mean (also percent).
d Binding of 125I-plasminogen to GAS in the presence of excess streptokinase and fibrinogen.
e vir type was determined as previously described (19).
f The emm ST was determined by using a protocol modified from the S. pyogenes emm sequence database.
g The emm pattern was determined as previously described (5, 23), except that the annealing temperatures varied between 56 and 62°C depending on the strain.
h Isolates NS244 and NS474 gave an unusual emm pattern, in that PCR product resulted only from reaction with primer set 2 rather than sets 1, 2, and 3, or set 1
only, as for traditional emm pattern ABC.
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positive isolates, invasive isolates bind more plasminogen both
directly and by a FSD pathway that is correlated with direct
plasminogen binding. Within the small clusters of PAM-posi-
tive isolates indistinguishable by the genotyping methods used,
invasive isolates always bound more plasminogen than isolates
from uncomplicated infections by both the direct and FSD
pathways. Possible reasons for plasminogen binding differ-
ences in these clusters might include variation in expression
levels or differential posttranslational processing or degrada-
tion. For PAM-negative isolates, which do not bind substantial
amounts of plasminogen directly, invasive isolates bind more
plasminogen by the FSD pathway. Together, these results sug-
gest that plasminogen acquisition may be an important viru-
lence determinant of GAS. The diversity of emm STs repre-
sented in this collection of isolates suggests that these
relationships between plasminogen binding and invasive capac-
ity do not depend on a small number of dominant clones.
The extent of direct plasminogen binding (4 to 81%) in this
study is similar to that found (9 to 69%) in a previous study
(35). Except for the conserved lysine residue in the A1 region,
which is thought to be responsible for the majority of plasmin-
ogen binding (43), the plasminogen binding domain in PAM is
highly divergent. The fact that PAM-negative isolates show
only moderate reactivity with plasminogen despite the pres-
ence of the gene for SEN, another plasminogen binding pro-
tein, suggests that SEN may not play a major role in plasmin-
ogen sequestration.
Isolates from invasive disease cases bind significantly more
plasminogen by the FSD pathway than do isolates from un-
complicated infections. Plasminogen acquisition by the FSD
pathway may therefore be a determinant for the propensity for
invasive disease. Plasmin activity owing to the FSD pathway is
resistant to inhibition by plasma proteins and has a half-life of
over 4 h as opposed to 20 min for plasmin activity owing to
direct plasminogen binding (37). The plasminogen activation
function of the complex also generates plasmin, which can bind
to surface receptors despite the presence of host physiological
inhibitors (12). The significant enhancement of plasminogen
binding has an absolute requirement for both fibrinogen and
streptokinase, a result consistent with earlier reports (37, 38).
The difference in fibrinogen binding between PAM-positive
and PAM-negative strains, correlation between fibrinogen bind-
ing and PAM-mediated plasminogen binding, and further en-
hancement of plasminogen binding by a combination of strep-
FIG. 1. Translated DNA sequences of the A1 and A2 repeats of the
13 PAM-positive isolates aligned with the amino acid sequence of the
prototype PAM gene. Isolates were considered PAM positive if they
produced a visible band on X-ray film with enhanced chemilumines-
cent detection (Supersignal chemiluminescent substrate; Pierce, Rock-
ford, Ill.) following Southern hybridization, indicating the presence of
a region with homology to the A1 and A2 plasminogen-binding repeat
region of PAM. *, residues identical to those of the PAM sequence; -,
gaps in the alignment. Percent amino acid sequence identity to PAM
is also given. Despite low sequence homology of isolate NS696 with the
prototype PAM amino acid sequence, the conservation of the lysine
residue in the A1 region thought to be critical to plasminogen binding
capacity of PAM, in addition to positive Southern hybridization anal-
ysis, resulted in this isolate being designated PAM positive.
FIG. 2. 125I-plasminogen binding to PAM-positive (F) and PAM-neg-
ative (E) GAS isolates from invasive and uncomplicated infections.
(A) Direct binding of 125I-plasminogen. (B) Binding of 125I-plasminogen
in the presence of molar excesses of streptokinase and fibrinogen. All
estimates were determined in triplicate, and data are presented as mean
values. Standard error of the mean was 0 to 6% of input 125I-plasminogen.
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tokinase and fibrinogen in PAM-positive isolates all point to the
occurrence of another receptor concomitant with PAM, or these
factors imply that PAM itself may be endowed with dual receptor
activity.
In contrast to PAM-positive isolates, neither the basal levels
of plasminogen binding nor the enhancement of the binding by
the FSD pathway was correlated with fibrinogen binding to the
surface of the PAM-negative isolates. This underscores the
different mechanisms of plasminogen binding between PAM-
positive and PAM-negative GAS strains.
The plasminogen system is only one of several factors im-
plicated in the invasive process of GAS. The streptococcal
pyrogenic exotoxin B of GAS possesses cysteine protease ac-
tivity that is also capable of degrading the host ECM (6, 20).
The lack of association between the plasminogen system and
GAS invasive disease in a previous report (36) may simply
reflect the analysis of the plasminogen system in isolation and
not one of several factors in an overall proteolytic model. In
this regard, overall the proteolytic activity of human isolates
has been associated with clinical signs of invasion (18, 34).
Alternatively, these previous findings may simply be indicative
of the complexity of the interaction of GAS and plasminogen
in the invasive process. As Boyle and Lottenberg noted, anal-
ysis of this complex system, involving at least four proteins, is
particularly difficult, as the bacterial components may be ex-
pressed only under certain environmental conditions (5).
In summary, we have demonstrated that GAS isolates from
NT invasive disease cases belonging to a wide range of emm
STs acquire more plasminogen than do isolates from uncom-
plicated infections by a pathway requiring fibrinogen and strep-
tokinase as cofactors. Among isolates containing the PAM
gene, invasive isolates also bind more plasminogen directly.
Subversion of the plasminogen system may be an important
virulence determinant in GAS, and future work will focus on
identifying the basis for higher plasminogen binding by inva-
sive isolates within and between GAS genotypes.
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